Format

Send to

Choose Destination
Transfus Med Rev. 2009 Apr;23(2):124-33. doi: 10.1016/j.tmrv.2008.12.004.

Properties of pathogen-inactivated plasma components.

Author information

1
Scottish National Blood Transfusion Service, Edinburgh, United Kingdom. chris.prowse@snbts.csa.scot.nhs.uk

Abstract

There are now 4 licensed technologies available for the pathogen inactivation of fresh frozen plasma in Europe. None of these are currently available in the United States, whereas in other geographic regions some are licensed others are not. This review addresses the different technologies available for the pathogen inactivation of plasma, their impact on the potency of the product, their efficacy in addressing microbiological contamination, as well as summarizing potential immunologic and toxicologic concerns. Published evidence of clinical efficacy is also reviewed as are various approaches to determining cost-effectiveness.

PMID:
19304113
DOI:
10.1016/j.tmrv.2008.12.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center